SentreHEART, Inc. Company Profile

16:07 EST 22nd January 2020 | BioPortfolio

SentreHEART, Inc., based in Redwood City, California, is a privately held medical device company that manufacturers the LARIAT Suture Delivery Device for remote delivery of a pre-tied suture loop. Innovation in catheter and suture delivery technology enables physicians to remotely deliver a 40mm pre-tied suture loop for immediate and complete soft tissue closure through access as small as 4.3mm and with no metal, clips or fabrics left behind. Regulatory clearance for soft tissue ligation and approximation has been received in the US, Europe, and Canada. For more information, please visit

News Articles [9 Associated News Articles listed on BioPortfolio]

AtriCure buys SentreHEART

AtriCure Inc. is paying $40mm up front in cash and stock to acquire closely held SentreHEART Inc. AtriCure could also hand over $260mm in earn-outs tied to SentreHEART’s Lariat percutaneous left atr...

AtriCure Enters Agreement to Acquire SentreHEART

AtriCure (NASDAQ:ATRC) has announced it has entered into a definitive agreement to acquire SentreHEART. As quoted in the press release: Under the terms of the agreement to acquire SentreHEART, the tra...

AtriCure agrees to buy SentreHEART in £248m deal

AtriCure has agreed to acquire US-based medical device company SentreHEART in a deal valued at around $300m (£248m) The deal includes an upfront payment of around $40m (33.1m) The post AtriCure agre...

SentreHEART announces initial clinical use of the LARIAT with EpiRAILprocedure for left atrial appendage exclusion

SentreHEART has completed nine First-In-Human procedures utilizing the LARIAT with EpiRAIL at John Paul II hospital in Krakow, Poland. The LARIAT with EpiRAIL is an epicardial-only, percutaneous appro...

Atricure to acquire Sentreheart, Lariat device

Sentreheart and its Lariat percutaneous, epicardial suture delivery device will be purchased by Atricure for a $40 million up -More- 

AtriCure Adds Lariat LAA Closure System With $300M SentreHeart Acquisition

AtriCure Inc. has closed a $300m structured deal to acquire SentreHEART Inc., a privately held developer of percutaneous left atrial appendage...   

AtriCure Completes Acquisition of SentreHEART

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has completed its previously announ...

AtriCure To Acquire SentreHEART For Atrial Fib Tech

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Left Atrial Appendage Closure With SentreHeart Lariat® Device

The study cohort will consist of up to 50 patients who are candidates for Left Atrial Appendage (LAA) closure in whom oral anticoagulation is contraindicated. Subjects evaluated for left ...

Companies [1 Associated Companies listed on BioPortfolio]

SentreHEART, Inc.

SentreHEART, Inc., based in Redwood City, California, is a privately held medical device company that manufacturers the LARIAT Suture Delivery Device for remote delivery of a pre-...

More Information about "SentreHEART, Inc." on BioPortfolio

We have published hundreds of SentreHEART, Inc. news stories on BioPortfolio along with dozens of SentreHEART, Inc. Clinical Trials and PubMed Articles about SentreHEART, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of SentreHEART, Inc. Companies in our database. You can also find out about relevant SentreHEART, Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topic

Medical Devices
The role of medical devices in healthcare is essential.  The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare.  Covering a wide range of products, from simple bandages to the...

Corporate Database Quicklinks

Searches Linking to this Company Record